Skip to main content
PolicySpeak
← All files
MUM

MUMC+

Academic / research · Netherlands

not in the EU Transparency RegisterThis organization files on consultations without a register number, so its record here is built from its filings alone. Register facts (staff, costs, accreditations) are not available for it.

3
positions filed
in the 665 files tracked
2
legislative files
of 665 tracked
1
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.

Track MUMC+ in PolicySpeak: request access →

Follow MUMC+

An email when this organization files on a consultation we publish.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Work at MUMC+? so we know who speaks for it.

Their record over time

MUMC+ filed 3 positions between 18 Sept 2025 and 13 Feb 2026, across 2 of the 665 legislative files tracked here, attaching a full position paper 1 time.

2025 · 2 filed2026 · 1 filed

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 13 Feb 2026source

The proposed relaxations within the IVDR legislation can have a positive impact on the development, implementation and application of LDTs within diagnostics. The increased flexibility and simplified procedures contribute to a more efficient use of clinical trials, which can ultimately lead to better patient care and innovation in medical diagnostics. 1.

Filed in Dutch · English published by the European Commission

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 18 Sept 2025source

1. Properly functioning CE labelled tests are taken out of production, as it is costly for manufacturers to comply with the CE IVD standard. This reduces the quality of diagnostics because alternatives are less of quality or do not exist at all. This cannot be the intention. 2. Exchange of LDTs in the absence of a CE IVD alternative (e.g. rare diseases or multicer studies) is not possible under current legislation.

Filed in Dutch · English published by the European Commission

European Competitiveness Fundfiled 10 Nov 2025PDFsource

Explicit inclusion of European Reference Networks (ERNs) in the ECF is vital for health competitiveness and rare disease care The current proposal for the European Competitiveness Fund (ECF), specifically Chapter V (Articles 36 and 37) on Health, biotech, agriculture and bioeconomy, aligns perfectly with the mission of European Reference Networks (ERNs).

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Put MUMC+ next to another organization. Same files, same register facts, side by side. Compare →

Turns up on the same files

Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.

Showing 5 of 16.

Is this your organization?

Everything on this page comes from MUMC+’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.